Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28951904 | 0.81 | DPP4 (0.37) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL21986229 | 0.74 | DPP4 (0.43) | DPP4DPP8DPP9 | |
| SCHEMBL15238182 | 0.74 | — | — | |
| SCHEMBL2605419 | 0.74 | — | — | |
| SCHEMBL19981833 | 0.72 | ALDH1A1 (0.41) | DPP4 | |
| SCHEMBL28056504 | 0.71 | DPP4 (0.46) | DPP4 | |
| SCHEMBL5140895 | 0.70 | DPP4 (0.47) | DPP4 | |
| SCHEMBL28834183 | 0.69 | DPP4 (0.48) | DPP4 | |
| SCHEMBL15639186 | 0.69 | DPP4 (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL8406330 | 0.69 | DPP4 (0.32) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748457-B2 | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors | LUPIN LIMITED (IN) | 2014-06-10 | — | — | US | disclosed |
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20120082635-A1 | 2-AMINO-2- [8-(DIMETHYL CARBAMOYL)- 8-AZA- BICYCLO [3.2.1] OCT-3-YL]-EXO- ETHANOYL DERIVATIVES AS POTENT DPP-IV INHIBITORS | LUPIN LIMITED (IN) | 2012-04-05 | — | — | US | disclosed |
| WO-2010146597-A1 | 2-AMINO-2- [8-(DIMETHYL CARBAMOYL)- 8-AZA- BICYCLO [3.2.1] OCT-3-YL]-EXO- ETHANOYL DERIVATIVES AS POTENT DPP-IV INHIBITORS | LUPIN LIMITED (IN) | 2010-12-23 | — | — | WO | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009037719-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2009-03-26 | — | — | WO | disclosed |
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | GENENTECH, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1943257-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7399869-B2 | N-blocked peptide proline boronate compounds; hyperproliferative disorders like cancer, neurodegeneration, cardiac hypertrophy, pain, migraine, neurotraumatic disease, cirrhosis, fibromatosis, and rheumatoid arthritis | GENENTECH, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7169806-B2 | Antidiabetic agents | FERRING BV (NL) | 2007-01-30 | — | — | US | disclosed |
| US-6911467-B2 | Antidiabetic agents | FERRING BV (NL) | 2005-06-28 | — | — | US | disclosed |
| CN-1192020-C | Antidiabetic agents | FERRING BV (NL) | 2005-03-09 | — | — | CN | disclosed |
| EP-1351932-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | Ferring BV (NL) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351932-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | Ferring BV (NL) | 2003-10-15 | — | — | EP | disclosed |
| US-20030096857-A1 | Novel antidiabetic agents | FERRING BV (NL) | 2003-05-22 | — | — | US | disclosed |
| US-20030096857-A1 | Novel antidiabetic agents | FERRING BV (NL) | 2003-05-22 | — | — | US | disclosed |
| CN-1402706-A | Antidiabetic agents | FERRING BV (NL) | 2003-03-12 | — | — | CN | disclosed |
| WO-2001040180-A3 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | FERRING BV (NL) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001040180-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | FERRING BV (NL) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040180-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | FERRING BV (NL) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20030096857-A1 | Novel antidiabetic agents | DPP4, SLC5A2, SLC2A4 | DPP4 1/4885DPP8 44/4885DPP9 62/4885 |
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | FAP, FIBP, FGFR1 | DPP4 305/4885DPP8 220/4885DPP9 145/4885 |
| US-20120082635-A1 | 2-AMINO-2- [8-(DIMETHYL CARBAMOYL)- 8-AZA- BICYCLO [3.2.1] OCT-3-YL]-EXO- ETHANOYL DERIVATIVES AS POTENT DPP-IV INHIBITORS | DPP7, DPP4, DPP8 | DPP4 2/4885DPP8 3/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.